Citi analyst Andrew Baum reiterated a Buy rating on AstraZeneca (NASDAQ: AZN) and opened a positive catalyst watch after shares ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE